Access to Care: Pharmaceutical Patents

Once a month, the Crohn's & Colitis Foundation (US) brings all staff together (from all the departments at the Foundation) to share information, resources, and updates.

Once a month, the Crohn's & Colitis Foundation (US) brings all staff together (from all the departments at the Foundation) to share information, resources, and updates.

In this episode of Arthritis Consumer Experts' Arthritis At Home, host Cheryl Koehn speaks with Laura Wingate, Chief Education, Support, and Advocacy Officer of the Crohn’s and Colitis Foundation of the USA, about the Patients and patents campaign.

This webinar will help you understand patents clearly as well as encourage patients and caregivers to promote more timely availability of generics and biosimilars.

In this episode of Arthritis Consumer Experts' Arthritis At Home, host Cheryl Koehn speaks with Deidre Mackechnie, Executive Officer of the Australian Patient Advocacy Alliance, about her organization’s partnering with the Patients and patents campaign.

A recent article published on BioSpace summarizes an analysis conducted by Sean Tu of the University of Alabama School of Law. Tu's work cites multiple examples of pharmas using what the authors term serial litigation to stave off would-be competitors for years, allowing them to keep prices high.

ACE submitted an Op-Ed to the Globe and Mail, Canada’s national newspaper of record in response to an article focused on whether Canada’s drug pricing policies discourage pharmaceutical companies from launching innovative therapies.

This report from the International Generic and Biosimilar Medicines Association looks at the various strategies...

Prescription drug prices continue to rise around the world, putting essential medications out of reach for too many people living with chronic diseases.

This Arthritis Consumer Experts Arthritis At Home explores why some medications are so expensive and the role pharmaceutical patents play in access to affordable treatment.

This Globe and Mail op-ed calls attention to how brand-name manufacturers are using the patent system to block affordable biosimilars and generics in Canada.